The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion

Amaya García-Fernández; Francisco Marı́n; Vanessa Roldán; Emilio Galcerá-Jornet; Juan Gabriel Martı́nez; Mariano Valdés; Francisco Sogorb; Professor Gregory Lip

doi:10.1016/j.ijcard.2016.04.167

Back

Shared by

Professor Gregory Lip

University of Liverpool

The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion

Article 2016 en

Authors

AG
Amaya García-Fernández
FM
Francisco Marı́n
VR
Vanessa Roldán

Related publications

Article2016

Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?

María Asunción Esteve‐Pastor, Amaya García-Fernández, Manuel Macı́as, Francisco Sogorb, Mariano Valdés, Vanessa Roldán, Javier Muñiz, Lina Badimón, Inmaculada Roldán, Vicente Bertoméu, Ángel Cequier, Professor Gregory Lip, Manuel Anguita, Francisco Marı́n

Article2016

Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion

Amaya García-Fernández, Francisco Marı́n, Vanessa Roldán, José M. Gómez-Sansano, Diana Hernández‐Romero, Mariano Valdés, Juan Gabriel Martı́nez, Francisco Sogorb-Garri, Professor Gregory Lip

Article2018

Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF Bleeding Scores

Marco Proietti, José Miguel Rivera‐Caravaca, María Asunción Esteve‐Pastor, Giulio Francesco Romiti, Francisco Marı́n, Professor Gregory Lip

Article2016

Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial

Keitaro Senoo, Professor Gregory Lip

Article2017

Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial

María Asunción Esteve‐Pastor, José Miguel Rivera‐Caravaca, Alena Shantsila, Vanessa Roldán, Professor Gregory Lip, Francisco Marı́n

The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion

Discussion(0)

Related publications

Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?

Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion

Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF Bleeding Scores

Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial

Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial